Scientists warn some weight-loss jabs could make the contraceptive pill less effective – MadeForMums
A new review highlights an important contraception warning for women taking tirzepatide weight-loss injections.
Weight-loss injections have transformed conversations around weight management, but there's an important contraception warning women taking one particular type need to know about.
A new review looking at GLP-1 weight-loss drugs and reproductive health has highlighted evidence that tirzepatide can affect how oral contraceptives are absorbed, potentially making the pill less reliable when women first start treatment or increase their dose.
The review found that the clinically significant interaction applies to tirzepatide, while available studies of semaglutide, liraglutide, exenatide and dulaglutide have not shown clinically significant reductions in exposure to oral contraceptives.
GLP-1 drugs work in several ways, including slowing down how quickly the stomach empties. This can change the speed at which medicines taken by mouth are absorbed.
According to the review, most GLP-1 drugs can alter the peak concentration or timing of some oral medicines without meaningfully changing overall exposure. Tirzepatide, however, has a stronger effect on gastric emptying early in treatment, particularly when treatment begins and following dose increases.
Studies cited by the researchers found reduced exposure to combined oral contraceptives when taken alongside tirzepatide.
The review says women using oral hormonal contraception should be counselled to use an additional barrier method, such as condoms, or switch to a non-oral form of contraception during tirzepatide initiation and dose escalation.
Its summary table recommends backup contraception until the maintenance dose has been reached and used for at least four weeks.
Contraceptive methods that don't rely on absorption through the digestive system aren't affected by this particular interaction. The researchers list:
Women taking tirzepatide who use the pill shouldn't stop or change their contraception without speaking to the healthcare professional responsible for their care.
This distinction matters. The review reports that available studies involving semaglutide, liraglutide, exenatide and dulaglutide haven't demonstrated a clinically significant reduction in oral contraceptive exposure.
Its table therefore states that backup contraception isn't required because of a drug interaction with oral contraceptives for these GLP-1 medicines.
However, there's another reason contraception has become an important conversation for some women taking weight-loss medication.
Potentially, for some women.
The researchers say weight loss and improvements in metabolic health may restore ovulation in some people, particularly those with polycystic ovary syndrome (PCOS). That could mean someone who previously believed they were unlikely to conceive finds their fertility has changed.
The review cites research involving 840 women with PCOS which found GLP-1 drugs improved natural pregnancy rates and menstrual regularity compared with metformin.
This doesn't mean weight-loss injections should be considered fertility treatments. Instead, the researchers say the findings underline the importance of discussing contraception even with women who have previously experienced infertility.
Current guidance recommends GLP-1 drugs aren't routinely used during pregnancy.
If pregnancy is discovered while taking one, the review recommends generally stopping the medication and seeking appropriate medical advice and follow-up. Women taking semaglutide who are planning a pregnancy are advised by US product labelling cited in the paper to stop at least two months before conception.
There is some reassurance for anyone who discovers they're pregnant after already taking a GLP-1 drug. The researchers say current human evidence hasn't shown a consistent increase in major congenital abnormalities following inadvertent early-pregnancy exposure.
However, evidence is still limited, and animal studies have raised safety concerns. The authors therefore conclude that women should receive individualised advice based on the specific medication they're taking, their pregnancy plans, contraception and wider health.
Read more:
Ruairidh is the Digital Lead on MadeForMums. He works with a team of fantastically talented content creators and subject-matter experts on MadeForMums.
